

Product supply shortage addressed for the *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Apotex Inc. and Jamp Pharma Corporation that the shortages for Apo-Ondansetron 4 mg/5 ml Oral Solution (DIN 02291967) and Jamp Ondansetron 0.8 mg/ml Oral Solution (DIN 02490617) respectively, have been resolved. Due to the long-term nature of these shortages, a transition period will be applied and, as a result, the LCA price policy will be reapplied to the following grouping effective **August 24, 2022**. The following grouping was removed from the Critical Supply Product List on **July 25, 2022**.

ONDANSETRON HCL DIHYDRATE

0.8 MG / ML ORAL SOLUTION

00002291967	APO-ONDANSETRON	APX	\$ 1.1360
00002490617	JAMP ONDANSETRON	JPC	\$ 1.1360
00002229639	ZOFRAN	NOV	\$ 2.2672

Removal of temporary benefit from the *Alberta Drug Benefit List (ADBL)*

Due to the shortage of Oxyneo 15 mg Controlled-Release Tablet (DIN 02372533) manufactured by Purdue Pharma, Apo-Oxycodone CR 15 mg Controlled-Release Tablet (DIN 02394766) manufactured by Apotex Inc. was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Purdue Pharma has advised Alberta Blue Cross that the shortage for Oxyneo 15 mg Controlled-Release Tablet (DIN 02372533) has been resolved.

As a result, Apo-Oxycodone CR 15 mg Controlled-Release Tablet (DIN 02394766) will no longer be considered a temporary benefit for the *ADBL* after **August 29, 2022**. The above grouping was removed from the Critical Supply Product List on **July 27, 2022**.

continued next page

continued from previous page

Product supply shortage addressed for the *Alberta Human Services Drug Benefit Supplement (HSDBS)*

Alberta Blue Cross has been advised by Insight Pharmaceuticals LLC that the shortage for Nix 10 mg/ml Topical Cream Rinse (DIN 00771368) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **September 12, 2022**. The following grouping was removed from the Critical Supply Product List on **August 11, 2022**.

PERMETHRIN

10 MG / ML TOPICAL RINSE

00000771368	NIX CREME	IPH	\$ 0.1907
00002231480	KWELLADA-P CREME	MTC	\$ 0.2328

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

